Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: Too alarming?

Journal of Hepatology

Volumn 65, Issue 5, 2016, Pages 1068-1069

  Zeng, Qing Lei ^a   Li, Zhi Qin ^a   Liang, Hong Xia ^a   Xu, Guang Hua ^b   Li, Chun Xia ^b   Zhang, Da Wei ^c   Li, Wei ^d   Sun, Chang Yu ^a   Wang, Fu Sheng ^c   Yu, Zu Jiang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b YAN'AN UNIVERSITY   (China)

^c BEIJING 302 HOSPITAL   (China)

^d HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; DIRECT ACTING ANTIVIRAL AGENT; INTERFERON; RIBAVIRIN; SOFOSBUVIR; UNCLASSIFIED DRUG;

ANTIVIRAL THERAPY; CANCER INCIDENCE; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; GENERAL HOSPITAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE STATUS; LETTER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; TREATMENT DURATION; TUMOR RECURRENCE; UNIVERSITY HOSPITAL; CHRONIC HEPATITIS C; HEPACIVIRUS; INCIDENCE; LIVER TUMOR;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; LIVER NEOPLASMS;

EID: 84994108075     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.07.029     Document Type: Letter

References (10)

1. [1] Zeng, Q.L., Zhang, J.Y., Zhang, Z., Wang, L.F., Wang, F.S., Sofosbuvir and ABT-450: terminator of hepatitis C virus?. World J Gastroenterol 19 (2013), 3199–3206.
2. [2] European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 63 (2015), 199–236.
3. [3] Reig, M., Marino, Z., Perello, C., et al. Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol 65 (2016), 719–726.
4. [4] Kozbial, K., Moser, S., Schwarzer, R., et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with SVR following IFN-free DAA treatment. J Hepatol 65 (2016), 856–858.
5. [5] Zeng, Q.L., Li, C.X., Zhang, D.W., et al. Letter: safety and efficacy of sofosbuvir plus daclatasvir with ribavirin for 12 weeks in Chinese treatment-experienced cirrhotic genotype 1b patients with HCV. Aliment Pharmacol Ther 43 (2016), 842–843.
6. [6] El-Serag, H.B., Kanwal, F., Richardson, P., Kramer, J., Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology 64 (2016), 130–137.
7. [7] Zeng, Q.L., Li, B., Zhang, X.X., et al. Clinical model for predicting hepatocellular carcinomas in patients with post-sustained virologic responses of chronic hepatitis C: a case control study. Gut Liver, 2016 In press.
8. [8] European Association for the Study of the Liver. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 55 (2011), 245–264.
9. [9] Meissner, E.G., Wu, D., Osinusi, A., et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 124 (2014), 3352–3363.
10. [10] Serti, E., Chepa-Lotrea, X., Kim, Y.J., et al. Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function. Gastroenterology 149 (2015), 190–200, e192.